Moreover, FGF21 serves as a diagnostic biomarker in metabolic diseases related to glucose and lipid metabolism, with elevated serum FGF21 levels observed in early-stage NAFLD patients. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.